Share Twitter LinkedIn Facebook Email Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH Chronic Lymphocytic Leukemia 2 Mins Read